ABSTRACT
Background Depression is a common and chronic comorbidity affecting approximately one in four people with type 2 diabetes (T2DM), and often lasting several years. Past systematic reviews have been unable to identify evidence for long-term (12+ months) antidepressant treatment outcomes in comorbid depression and type 2 diabetes. These reviews are >10years old, included only randomised controlled trials or had limited search strategies. We aimed to systematically review observational studies for long-term outcomes of antidepressant treatment in adults with comorbid depression and T2DM, including broader, up-to-date searches.
Methods and findings This review was pre-registered on PROSPERO (CRD42020182788). We searched seven databases using terms related to depression, T2DM and antidepressant medication. From 14,389 reports retrieved, 63 were screened at full text stage and 0 met inclusion criteria. The reasons for exclusion at full text stage were: Studies did not meet inclusion criteria for antidepressant treatment (n = 50); studies did not meet inclusion criteria for T2DM (n = 36); studies did not meet inclusion criteria for depression (n = 29); studies did not include follow-up time (n = 25); studies did not meet inclusion criteria for observational study (n = 14); studies did not include any measurable outcomes (n = 5); studies did not include a suitable comparison (n = 3).
Conclusions We found no evidence concerning long-term outcomes of antidepressant treatment in individuals with comorbid depression and T2DM. Insufficient ascertainment of antidepressant prescription, case identification, and short follow-up times are the primary reasons for this. Research is urgently required to determine long-term outcomes associated with antidepressant treatment in this patient group.
Competing Interest Statement
Annie Jeffery reports financial support was provided by National Institute for Health Research. Joshua Buckman, Joseph Hayes reports a relationship with Wellcome Trust that includes: funding grants. Ian Wong, David Osborn, Joseph Hayes reports a relationship with National Institute for Health Research that includes: funding grants. David Osborn, Ian Wong reports a relationship with NIHR University College London Hospitals Biomedical Research Centre that includes: funding grants. Joshua Buckman reports a relationship with Royal College of Psychiatrists that includes: funding grants. Ian Wong reports a relationship with Amgen Inc that includes: funding grants. Ian Wong reports a relationship with BristolMyers Squibb that includes: funding grants. Ian Wong reports a relationship with Pfizer that includes: funding grants. Ian Wong reports a relationship with Janssen Pharmaceuticals Inc that includes: funding grants and speaking and lecture fees. Ian Wong reports a relationship with Bayer Corporation that includes: funding grants. Ian Wong reports a relationship with GSK that includes: funding grants. Ian Wong reports a relationship with Novartis that includes: funding grants. Ian Wong reports a relationship with Hong Kong Research Grants Council that includes: funding grants. Ian Wong reports a relationship with he Food and Health Bureau of the Government of the Hong Kong Special Administrative Region that includes: funding grants. Ian Wong reports a relationship with National Health and Medical Research Council in Australia that includes: funding grants. Ian Wong reports a relationship with European Commission that includes: funding grants. Ian Wong reports a relationship with Medice that includes: funding grants. Ian Wong reports a relationship with Jacobson Medical that includes: board membership.
Funding Statement
This report is independent research funded by the National Institute for Health Research ARC North Thames. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos